CBB, respectfully, I recommend you take a deep breadth. I haven't seen anything, including KD Phamra, presenting any threat to the Vascepa franchise for the treatment of CVD, nor, as a better alternative adjunct therapy to potential first line SOC candidates under investigation.
Icosapent Ethyl's unique qualities are supported by Preston Mason's 30 + years of research. His papers reflect his exhaustive approach to understanding a wide range of FA's MOA, particularly, their functional roles within endothelial membranes. If a different FA could demontrate superior benfits on "endothelial functionality", Preston Mason would have uncovered it years ago imo.
It's not helpful to assume that KD Pharma's strategy included circumventing Amarin's patents. I would go so far as to say, their drug is not superior in effects on endothelial functionality, but likely, their research found "unexpected" benefits in the indications that they are pursuing.
Moreover, you're wasting energy in my view, to suggest the expediture and focus to start a trial for COVID-19 from scratch, since we have thousands of RWE patients who have tested positive, and or, have escalated to hospitalization etc.. to draw conclusions from. Elisabeth has already indicated, that they're having active discussions with doctors around the world to determine if Vascepa is showing potential benefits for COVID-19.
ILT
News 
Market Data 
Discover 
AI
